Basilea Pharmaceutica AG
SIX:BSLN
Basilea Pharmaceutica AG
SIX:BSLN
Price:
41.2 CHF
1.23%
Updated:
May 8, 2024
Basilea Pharmaceutica AG
Operating Income
|
Basilea Pharmaceutica AG
Operating Income Peer Comparison
Comparables:
ADCT
ACIU
CRSP
IDIA
KURN
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Operating Income
CHf19.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Operating Income
-$166m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Operating Income
-CHf53.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Operating Income
-$222.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Operating Income
-CHf803m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-152%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Operating Income
-CHf8.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
See Also
What is Basilea Pharmaceutica AG's Operating Income?
Operating Income
19.2m
CHF
19.2m
CHF
Based on the financial report for Dec 31, 2023, Basilea Pharmaceutica AG's Operating Income amounts to 19.2m CHF.
What is Basilea Pharmaceutica AG's Operating Income growth rate?
Operating Income CAGR 1Y
4%
4%
Over the last year, the Operating Income growth was 4%.
You don't have any saved screeners yet
